Pharmaceutical giant Novartis is making a big purchase. The Swiss company is purchasing U.S. Endocyte for $2.1 billion. Endocyte is currently conducting clinical trials for radiopharmaceuticals, which are drugs that help diagnose and target tumors. These radiopharmaceuticals could be used to treat men with metastatic castration-resistant prostate cancer. “Today’s announcement about the proposed acquisition of … Continue reading “Novartis is Buying Endocyte for $2.1 Billion”
